ReviewCurrent opinion in immunology2019
Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?
Review in Current opinion in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Zika virus exacerbates encephalomyelitis by inducing the production of T cell-attracting chemokines in astrocytes.International immunology · 2026Article
- Improved and customized dengue serodiagnostics through combined NS1/IgM testing and novel dual-cut-off IgG ELISA.PLoS neglected tropical diseases · 2026Article
- Integrative immunogenomic strategy for designing a multi-epitope vaccine against Zika and Dengue viruses.Scientific reports · 2026Article
- Dengue Dilemma: Navigating Cross-Reactivity and Immune Challenges.Current topics in microbiology and immunology · 2026Review
- Resurgence of Chikungunya virus: rising global threat and challenges in its mitigation.Frontiers in pharmacology · 2026Review
- Identification of Small Molecules as Zika Virus Entry Inhibitors.International journal of molecular sciences · 2025Article
- B-cell epitope mapping of Orthoflavivirus zikaense in mother-newborn immune interaction reveals postnatal immune signatures.Scientific reports · 2025Article
- Human T Cell Responses to Flavivirus Vaccines.European journal of immunology · 2025Review
- High seroprevalence of antibodies to Dengue, Chikungunya, and Zika viruses in Dire Dawa, Ethiopia: A cross-sectional survey in 2024.PLoS neglected tropical diseases · 2025Article
- Ultrasensitive Peptide-Based Electrochemical Biosensor for Universal Diagnostic of Dengue.Biosensors · 2025Article
- Transient Expression of Zika NS2B Protein Antigen inACS omega · 2025Article
- A low pre-existing anti-NS1 humoral immunity to DENV is associated with microcephaly development after gestational ZIKV exposure.PLoS neglected tropical diseases · 2025Article
- Design, development, and validation of multi-epitope proteins for serological diagnosis of Zika virus infections and discrimination from dengue virus seropositivity.PLoS neglected tropical diseases · 2024Article
- Did COVID-19 or COVID-19 Vaccines Influence the Patterns of Dengue in 2021? An Exploratory Analysis of Two Observational Studies from North India.The American journal of tropical medicine and hygiene · 2023Article
- Use of Envelope Domain III Protein for the Detection of IgG Type Antibodies Specific to Zika Virus by Indirect ELISA.Diagnostics (Basel, Switzerland) · 2023Article
- Structural and immunological basis of cross-reactivity between dengue and Zika infections: Implications in serosurveillance in endemic regions.Frontiers in microbiology · 2023Review
- Development of an Anti-Zika and Anti-Dengue IgM ELISA Assay: Evaluation of Cross Reactivity and Validation.Tropical medicine and infectious disease · 2022Article
- Zika Virus Replication in a Mast Cell Model is Augmented by Dengue Virus Antibody-Dependent Enhancement and Features a Selective Immune Mediator Secretory Profile.Microbiology spectrum · 2022Article
- Review
- Zika vector competence data reveals risks of outbreaks: the contribution of the European ZIKAlliance project.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Zika and the four serotypes of dengue are closely related flaviviruses that share a high degree of structural and sequence homology and co-circulate in many regions of the world. Here, we review recent studies investigating antigenic cross-reactivity between the two viruses. We discuss the pathogenic and protective roles of cross-reactive anti-viral antibody and T cell responses, respectively, in modulating the outcome of secondary dengue or Zika infection. Based on recent findings and increased incidence of severe disease in seronegative recipients of the first dengue vaccine to be licensed, we propose that the time has come to focus on developing pan-flavivirus vaccines that protect against Zika and four dengue serotypes by eliciting protective cross-reactive T cell responses while concomitantly reducing production of cross-reactive antibodies that can exacerbate disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.